Physician profile
Ellen L Mausner
NPI 1740293745
$3,538.29
in general payments reported to CMS, 2019-2025
8 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2021: $626 · 2022: $478 · 2023: $242 · 2024: $738 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $994.68 | 2019-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $623.54 | 2019-2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $599.55 | 2022-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $399.94 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $349.23 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $303.37 | 2021-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $142.98 | 2025 | Cobenfy |
| Tris Pharma INC | $125.00 | 2025 | Quillichew Er, Dyanavel Xr, Quillivant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Mausner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.